Teacher Retirement System of Texas Acquires 5,594 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Teacher Retirement System of Texas boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 17.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,516 shares of the biopharmaceutical company's stock after buying an additional 5,594 shares during the period. Teacher Retirement System of Texas' holdings in Halozyme Therapeutics were worth $1,794,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $29,000. CBIZ Investment Advisory Services LLC bought a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its holdings in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after buying an additional 197 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $69,000. Finally, Parkside Financial Bank & Trust boosted its stake in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the sale, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 31,697 shares of company stock worth $1,754,451 over the last ninety days. Company insiders own 2.40% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have issued reports on HALO shares. Benchmark reissued a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company dropped their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. Piper Sandler boosted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Finally, HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a report on Thursday, March 6th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $62.78.

Halozyme Therapeutics Price Performance

Shares of HALO stock traded down $0.03 during trading hours on Monday, reaching $63.81. 1,641,666 shares of the company were exchanged, compared to its average volume of 1,378,293. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock's fifty day moving average is $59.34 and its two-hundred day moving average is $54.84. The company has a market cap of $7.88 billion, a price-to-earnings ratio of 18.60, a P/E/G ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.